Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.47 |
| ▸ | DRD3 | P35462 | 6/20 | 0.47 |
| ▸ | HTR2C | P28335 | 3/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.42 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.42 |
| ▸ | BCL2 | P10415 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11087883 | 0.83 | PDE3B (0.45) | DRD2DRD3HTR2CPDE3BPDE3A | |
| SCHEMBL10840936 | 0.83 | PPARD (0.41) | DRD2PDE3BPDE3AHTR2AMTNR1A | |
| SCHEMBL6757612 | 0.81 | AR (0.43) | DRD2HTR2A | |
| SCHEMBL5681873 | 0.80 | ESR1 (0.57) | DRD2DRD3HTR2CPDE3BPDE3A | |
| SCHEMBL11748097 | 0.78 | DRD2 (0.43) | DRD2DRD3HTR2CPDE3BPDE3A | |
| SCHEMBL21243002 | 0.77 | AR (0.40) | DRD2 | |
| SCHEMBL30499354 | 0.77 | AR (0.40) | DRD2 | |
| SCHEMBL13091374 | 0.77 | AR (0.40) | DRD2 | |
| SCHEMBL4133012 | 0.77 | AR (0.40) | DRD2 | |
| SCHEMBL5682850 | 0.77 | ESR1 (0.51) | DRD2DRD3CYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9321730-B2 | Method of making and administering quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2016-04-26 | — | — | US | claimed |
| EP-2188259-B1 | QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS | UNIV HONG KONG POLYTECHNIC (CN) | 2013-11-06 | — | — | EP | claimed |
| US-20090054482-A1 | Method of making and administering quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2009-02-26 | — | — | US | claimed |
| CN-116272943-B | Carbon-based nonmetallic catalyst and preparation method and application thereof | 遵义医科大学 | 2024-06-11 | — | — | CN | disclosed |
| CN-116272943-A | Carbon-based nonmetallic catalyst and preparation method and application thereof | 遵义医科大学 | 2023-06-23 | — | — | CN | disclosed |
| CN-109988106-B | Amine compound for inhibiting SSAO/VAP-1 and application thereof in medicine | 广东东阳光药业有限公司 | 2023-03-31 | — | — | CN | disclosed |
| CN-113264876-B | Method for selectively catalyzing and hydrogenating aromatic heterocyclic compounds by non-hydrogen participation | 延安大学 | 2022-11-29 | — | — | CN | disclosed |
| CN-113264876-A | Method for selectively catalyzing and hydrogenating aromatic heterocyclic compounds by non-hydrogen participation | 延安大学 | 2021-08-17 | — | — | CN | disclosed |
| EP-2733138-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE TETRAHYDROQUINOLINE | HAMARI CHEMICALS LTD (JP) | 2016-09-28 | — | — | EP | disclosed |
| US-9321730-B2 | Method of making and administering quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2016-04-26 | — | — | US | disclosed |
| US-9321730-B2 | Method of making and administering quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2016-04-26 | — | — | US | disclosed |
| EP-2733138-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE TETRAHYDROQUINOLINE | Hamari Chemicals, Ltd. (JP) | 2014-05-21 | — | — | EP | disclosed |
| EP-2188259-B1 | QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS | UNIV HONG KONG POLYTECHNIC (CN) | 2013-11-06 | — | — | EP | disclosed |
| US-20090054482-A1 | Method of making and administering quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2009-02-26 | — | — | US | disclosed |
| US-20090054482-A1 | Method of making and administering quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2009-02-26 | — | — | US | disclosed |
| US-20090054482-A1 | Method of making and administering quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2009-02-26 | — | — | US | disclosed |
| US-4014877-A | MICROBIOCIDES | RIKER LABORATORIES, INC. (US) | 1977-03-29 | — | — | US | disclosed |
| US-4001243-A | ANTI-MICROBIAL | RIKER LABORATORIES, INC. (US) | 1977-01-04 | — | — | US | disclosed |
| US-3985882-A | ADMISTERING | RIKER LABORATORIES, INC. (US) | 1976-10-12 | — | — | US | disclosed |
| US-3969463-A | MICROBIOCIDE | RIKER LABORATORIES, INC. (US) | 1976-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054482-A1 | Method of making and administering quinoline derivatives as anti-cancer agents | HCCS, GLS2, NQO1 | DRD2 3202/4885DRD3 3826/4885HTR2C 2371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.